# Semax and Selank: Cognitive Peptide Research > Semax and Selank are Russian developed peptides studied for cognition and stress, with animal data far ahead of human trials. - URL: https://www.lifeconverted.com/learn/semax-selank-cognitive-research - Category: Longevity & Wellness - Author: Tom Gallagher, Senior Editor - Published: 2026-09-08 - Updated: 2026-09-25 - Reading time: 3 min - Keywords: semax selank, semax research, selank research, cognitive peptides, nootropic peptides --- Semax and Selank are two of the oldest synthetic peptides still being actively researched. Both came out of Soviet and post Soviet pharmacology labs decades ago. Both are approved and sold as prescription drugs in Russia. Neither has ever gone through FDA review, and neither has the kind of large scale randomized trial base that would settle the cognition and stress claims made about them. That is the bottom line. What follows is where these peptides came from, what the actual published data shows, and where the evidence runs thin. ## Origins in Russian research Semax and Selank both trace back to the Institute of Molecular Genetics in Moscow, working from a research line built on small proline containing peptides called glyprolines. The idea behind this family of peptides is that short, stable amino acid sequences derived from natural hormones could influence brain chemistry without the side effect profile of the parent hormone. Semax is built from a fragment of adrenocorticotropic hormone, or ACTH, with a Pro Gly Pro tail attached to slow its breakdown. Selank was developed from tuftsin, an immune signaling peptide, using the same stabilization approach. [Ashmarin and colleagues](https://pubmed.ncbi.nlm.nih.gov/15837162/) describe this broader family of natural and modified glyproline peptides, framing Semax and Selank as part of a deliberate effort to make short regulatory peptides that survive long enough in the body to do something. That survival question matters more than it sounds. Most small peptides get chewed up by blood enzymes within minutes. [Zolotarev and colleagues](https://pubmed.ncbi.nlm.nih.gov/16637290/) traced this kind of breakdown using tritium labeled peptides, and the short half life of unmodified peptides is a big part of why Semax and Selank were engineered with extra stability built in rather than used in their native form. Both peptides were approved for use in Russia decades ago, Semax for conditions involving reduced cerebral blood flow and cognitive decline, Selank for anxiety related complaints. Approval in that regulatory system does not carry over to the United States, the European Union, or most other jurisdictions, and it does not reflect the same evidentiary bar the FDA uses. ## Cognition and stress findings The mechanistic case for Semax rests partly on enzyme inhibition. [Kost and colleagues](https://pubmed.ncbi.nlm.nih.gov/11443939/) found that both Semax and Selank inhibit enzymes in human serum that break down enkephalins, the body's own opioid like signaling peptides. Slowing that breakdown could, in theory, extend the activity of enkephalin signaling involved in mood and stress response. That is a laboratory finding on isolated serum enzymes, not evidence of a clinical effect in a living person. Brain imaging work adds a more direct look at cognition. [Panikratova and colleagues](https://pubmed.ncbi.nlm.nih.gov/32342318/) used a functional connectomic approach, essentially mapping how different brain regions talk to each other, to study how Semax and Selank shift these connectivity patterns. This is real human data and a genuinely interesting method, but it is a small study looking at brain network activity, not a trial measuring memory scores, attention, or diagnosed anxiety outcomes. On the stress side, [Leonidovna and colleagues](https://pubmed.ncbi.nlm.nih.gov/32621722/) studied Selank's effect on cytokine levels under social stress conditions, reporting changes in inflammatory signaling. Cytokines are chemical messengers of the immune system, and shifts in this direction are consistent with a stress dampening effect, but cytokine levels are a biomarker, not a measured behavioral or clinical outcome. Animal work extends the picture further. [Slominsky and colleagues](https://pubmed.ncbi.nlm.nih.gov/28702721/) tested both peptides in rats with a chemically induced Parkinson's disease like condition, using the neurotoxin 6 hydroxydopamine to damage dopamine producing neurons. Both peptides affected motor behavior in these animals, which researchers read as a sign the peptides influence dopamine pathways relevant to movement and possibly cognition. Rat behavior in a toxin induced model is informative for mechanism, but it is several steps removed from a human patient. There is also older work on Semax's core Pro Gly Pro fragment. [Medvedeva and colleagues](https://pubmed.ncbi.nlm.nih.gov/25850296/) looked at how this tripeptide changed gene expression in rat brain tissue after a stroke like injury, finding shifts in genes tied to inflammation and tissue repair. Again, this is rodent tissue analysis, useful for building a mechanistic story but not proof of a cognitive benefit in people. Semax and Selank have also turned up in vascular research. [Liapina and colleagues](https://pubmed.ncbi.nlm.nih.gov/16634437/) compared the anticoagulant properties of several proline containing peptides, including Semax and Selank, alongside other glyprolines. Anticoagulant activity, if confirmed at meaningful levels, would matter for anyone combining these peptides with blood thinning medications, a detail worth being aware of even at the research stage. ## Evidence quality review Here is where the enthusiasm needs a hard look. Most of what exists on Semax and Selank falls into three buckets: rodent behavior studies, isolated enzyme or cytokine assays, and small human studies published in Russian pharmacology journals that rarely get replicated by independent labs outside that system. The functional connectomic study from Panikratova and colleagues is one of the more direct human brain measurements available, and it still involves a small sample studied with an exploratory imaging method, not a controlled trial with a defined cognitive endpoint. No large randomized controlled trial testing Semax or Selank against placebo for memory, focus, or diagnosed anxiety has been published in a widely indexed international journal. Safety data is similarly thin. [Kobylyanskii and colleagues](https://pubmed.ncbi.nlm.nih.gov/29063333/) tested several biologically active peptides, including compounds from this same research tradition, for toxic effects on mouse embryonic stem cells, a useful early screening step but not a substitute for long term human safety monitoring. None of this means the mechanistic findings are wrong. It means the chain from enzyme inhibition, to cytokine shifts, to rat behavior, to an actual claim about human focus or calm has several missing links. Reporting on Semax and Selank honestly means naming those gaps rather than smoothing over them. ## Regulatory status Semax and Selank are approved prescription drugs in Russia, sold there as nasal drops. That approval does not extend anywhere else. In the United States, both are unapproved compounds. They have no FDA approved indication, and they are not legal to market as treatments for anxiety, memory loss, or any other condition here. Where they appear in research contexts outside Russia, they are typically sold and studied as research chemicals, not as medicine. If you are trying to place these peptides in the wider peptide research world, LifeConverted's [peptide reference library](/all-peptides) covers where individual compounds stand on approval status and available research, which is a useful starting point before reading further into any single peptide's literature. ## Common questions **Are Semax and Selank approved medications in the United States?** No. Both are approved and sold as prescription products in Russia, but neither has FDA approval or an approved medical use in the United States. **Do Semax and Selank have solid human clinical trial data?** Human data exists but is mostly small, older, and published in Russian language journals with limited peer review outside that system. Much of the mechanistic work is done in animals. **What is the connection between Semax and the Pro Gly Pro tripeptide?** Semax contains a Pro Gly Pro sequence attached to a fragment of ACTH, and this small tripeptide fragment has been studied on its own for effects on gene expression after brain injury. *This article is for education only. It is not medical advice. Compounds discussed here are sold for research purposes. Talk to a licensed clinician before making health decisions.* ## FAQ ### Are Semax and Selank approved medications in the United States? No. Both are approved and sold as prescription products in Russia, but neither has FDA approval or an approved medical use in the United States. ### Do Semax and Selank have solid human clinical trial data? Human data exists but is mostly small, older, and published in Russian language journals with limited peer review outside that system. Much of the mechanistic work is done in animals. ### What is the connection between Semax and the Pro Gly Pro tripeptide? Semax contains a Pro Gly Pro sequence attached to a fragment of ACTH, and this small tripeptide fragment has been studied on its own for effects on gene expression after brain injury. ## Sources - Panikratova YR et al., 2020, Dokl Biol Sci: https://pubmed.ncbi.nlm.nih.gov/32342318/ - Slominsky PA et al., 2017, Dokl Biol Sci: https://pubmed.ncbi.nlm.nih.gov/28702721/ - Liapina LA et al., 2006, Izv Akad Nauk Ser Biol: https://pubmed.ncbi.nlm.nih.gov/16634437/ - Leonidovna YA et al., 2021, Curr Rev Clin Exp Pharmacol: https://pubmed.ncbi.nlm.nih.gov/32621722/ - Kost NV et al., 2001, Bioorg Khim: https://pubmed.ncbi.nlm.nih.gov/11443939/ - Medvedeva EV et al., 2014, Mol Biol (Mosk): https://pubmed.ncbi.nlm.nih.gov/25850296/ --- Published by LifeConverted, https://www.lifeconverted.com/learn/semax-selank-cognitive-research